BR0109875A - Tratamento de doenças respiratórias - Google Patents

Tratamento de doenças respiratórias

Info

Publication number
BR0109875A
BR0109875A BR0109875-6A BR0109875A BR0109875A BR 0109875 A BR0109875 A BR 0109875A BR 0109875 A BR0109875 A BR 0109875A BR 0109875 A BR0109875 A BR 0109875A
Authority
BR
Brazil
Prior art keywords
treatment
respiratory diseases
glycopyrrolate
exerts
administration
Prior art date
Application number
BR0109875-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Robin Mark Bannister
Andrew John Mcglashan Richards
Julian Clive Gilbert
David A V Morton
John Staniforth
Original Assignee
Arakis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0109875(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arakis Ltd filed Critical Arakis Ltd
Publication of BR0109875A publication Critical patent/BR0109875A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
BR0109875-6A 2000-04-07 2001-04-09 Tratamento de doenças respiratórias BR0109875A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008660.3A GB0008660D0 (en) 2000-04-07 2000-04-07 The treatment of respiratory diseases
PCT/GB2001/001606 WO2001076575A2 (en) 2000-04-07 2001-04-09 The treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
BR0109875A true BR0109875A (pt) 2004-07-20

Family

ID=9889490

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109875-6A BR0109875A (pt) 2000-04-07 2001-04-09 Tratamento de doenças respiratórias

Country Status (25)

Country Link
US (3) US7229607B2 (https=)
EP (3) EP1267866B2 (https=)
JP (1) JP5042426B2 (https=)
CN (3) CN101181263B (https=)
AT (1) ATE330585T2 (https=)
AU (2) AU2004242450B2 (https=)
BE (1) BE2013C023I2 (https=)
BR (1) BR0109875A (https=)
CA (1) CA2405705C (https=)
CY (1) CY1105120T1 (https=)
DE (1) DE60120936T3 (https=)
DK (1) DK1267866T4 (https=)
ES (2) ES2266242T5 (https=)
GB (1) GB0008660D0 (https=)
HK (1) HK1050846B (https=)
HU (2) HU230958B1 (https=)
IL (2) IL151791A0 (https=)
LU (2) LU92166I2 (https=)
MX (1) MXPA02009718A (https=)
NO (3) NO336142B1 (https=)
NZ (2) NZ535284A (https=)
PL (1) PL364024A1 (https=)
PT (1) PT1267866E (https=)
WO (1) WO2001076575A2 (https=)
ZA (1) ZA200207420B (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
ES2474199T3 (es) 2000-11-30 2014-07-08 Vectura Limited Composiciones farmacéuticas para inhalaci�n
DE60140268D1 (de) 2000-11-30 2009-12-03 Vectura Ltd Partikel zur verwendung in einer pharmazeutischen zusammensetzung
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
EP1389468A4 (en) 2001-05-23 2007-01-10 Tanabe Seiyaku Co COMPOSITIONS FOR PROMOTING BONE FRACTURE HEALING
CN1537018A (zh) 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
ES2342463T3 (es) * 2002-03-01 2010-07-07 Chiesi Farmaceutici S.P.A. Formulacion superfina de formoterol.
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP2287326A1 (en) * 2003-08-08 2011-02-23 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
ATE530165T1 (de) * 2003-11-14 2011-11-15 Baxter Int Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen
ES2413011T3 (es) 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
ES2309705T3 (es) * 2004-02-06 2008-12-16 MEDA PHARMA GMBH & CO. KG Nueva combinacion de anticolinergico y beta-mimeticos para el tratamiento de enfermedades respiratorias.
EP1713471B1 (en) * 2004-02-06 2012-01-18 MEDA Pharma GmbH & Co. KG Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
RU2006132043A (ru) * 2004-02-06 2008-03-20 МЕДА Фарма ГмбХ унд Ко.КГ (DE) Комбинация и фармацевтический препарат для лечения ринита
EP1720577A2 (en) * 2004-02-27 2006-11-15 Altana Pharma AG Ciclesonide and glycopyrronium combination
EP1737499A4 (en) * 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CA2568834A1 (en) * 2004-06-29 2006-01-12 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and an anticholinergic
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
WO2006026502A1 (en) 2004-08-27 2006-03-09 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
JP5288791B2 (ja) * 2005-01-28 2013-09-11 武田薬品工業株式会社 難水溶性物質含有微細化組成物
EP1863476B1 (en) 2005-03-16 2016-02-03 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
US7915303B2 (en) * 2005-03-24 2011-03-29 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
EP1978933A2 (en) * 2005-12-15 2008-10-15 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
NZ591969A (en) * 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB2434098A (en) * 2005-12-23 2007-07-18 Novartis Ag Process for the preparation of an inhalable dry powder formulation
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
BRPI0820745A2 (pt) * 2007-12-13 2015-06-16 Novartis Ag Compostos orgânicos
ES2396471T3 (es) * 2007-12-13 2013-02-21 Novartis Ag Procedimiento para reducir la tendencia de una sal de glicopirronio a agregarse durante el almacenamiento
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
CA2716936C (en) * 2008-02-26 2018-06-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
DK2400950T3 (da) 2009-02-26 2019-07-29 Glaxo Group Ltd Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL3111927T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
BR112012015334A2 (pt) 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
KR20120106753A (ko) 2009-12-23 2012-09-26 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 에어로졸 제제
SG181870A1 (en) 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
EP2515855B3 (en) 2009-12-23 2023-05-03 Chiesi Farmaceutici S.p.A. Combination therapy for COPD
BR112013007304B1 (pt) * 2010-09-29 2021-12-14 Pulmatrix, Inc. Pós secos de cátion de metal monovalente para inalação
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
HUE041858T2 (hu) 2011-08-01 2019-05-28 Univ Monash Inhalálásra szolgáló eljárás és kiszerelés
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
WO2015094927A1 (en) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants
RS57687B1 (sr) 2013-12-30 2018-11-30 Chiesi Farm Spa Pod pritiskom stabilan aerosolni rastvor kompozicije glikopironijum bromida i kombinacije formoterola
DK3689332T3 (da) 2014-09-09 2026-03-23 Vectura Ltd Formulering, som omfatter glycopyrrolat, fremgangsmåde og apparat
MY196072A (en) * 2014-09-15 2023-03-13 Verona Pharma Plc Liquid Inhalation Formulation Comprising RPL554
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
CN108024967B (zh) * 2015-06-15 2021-12-21 库姆制药有限责任公司 格隆铵脂肪酸盐及其制备方法
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
AU2019477296A1 (en) 2019-12-02 2022-04-14 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5849263A (en) 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
AR002009A1 (es) * 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5690374A (en) * 1996-04-19 1997-11-25 Nor-Easter Enterprises, Inc. Shock-absorbing tool handle
CN100391942C (zh) 1996-11-11 2008-06-04 索佛特克两合公司 对映异构纯的碱性芳基-环烷基-羟基羧酸酯,其制备方法及其在药品中的应用
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
CA2277801C (en) * 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JP2001511160A (ja) * 1997-02-05 2001-08-07 ヤゴ リサーチ アクチェンゲゼルシャフト 医学用エアゾール配合物
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
ES2234266T3 (es) * 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
JP4672143B2 (ja) * 1998-08-04 2011-04-20 ヤゴテック アーゲー 医薬用エーロゾル製剤
PL200941B1 (pl) * 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
WO2001008681A1 (en) * 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6758795B2 (en) * 2000-08-22 2004-07-06 Stephen Barber Adjustable water-fillable exercise weights
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
TWI509631B (zh) 2011-02-25 2015-11-21 漢高智慧財產控股公司 用於電子裝置之可燒結銀薄片黏著劑

Also Published As

Publication number Publication date
US20030068280A1 (en) 2003-04-10
HUP0301518A2 (hu) 2003-08-28
EP1267866B2 (en) 2016-07-20
DK1267866T3 (da) 2006-10-23
DE60120936T2 (de) 2006-11-02
WO2001076575A2 (en) 2001-10-18
HU230958B1 (hu) 2019-06-28
US20080220073A1 (en) 2008-09-11
NO336142B1 (no) 2015-05-26
CA2405705C (en) 2011-06-07
AU2004242450B2 (en) 2010-06-03
DE60120936T3 (de) 2016-11-17
CN101181263B (zh) 2011-07-06
US7368104B2 (en) 2008-05-06
WO2001076575A3 (en) 2002-03-28
MXPA02009718A (es) 2003-05-27
AU2010200660B2 (en) 2012-04-19
HK1050846B (en) 2007-01-26
PL364024A1 (en) 2004-11-29
US8029768B2 (en) 2011-10-04
EP1449528B1 (en) 2018-08-08
DE60120936D1 (de) 2006-08-03
AU8930601A (en) 2001-10-23
LU92166I2 (fr) 2014-03-13
ES2687751T3 (es) 2018-10-29
BE2013C023I2 (https=) 2020-06-24
EP1267866B1 (en) 2006-06-21
NO20024708L (no) 2002-10-24
CN1422154A (zh) 2003-06-04
JP2003530344A (ja) 2003-10-14
NZ521476A (en) 2004-10-29
PT1267866E (pt) 2006-10-31
CN1292745C (zh) 2007-01-03
ZA200207420B (en) 2003-09-16
NO20024708D0 (no) 2002-10-01
EP1267866A2 (en) 2003-01-02
NO2015024I2 (no) 2015-11-25
IL151791A (en) 2015-05-31
LU92393I2 (fr) 2015-11-02
AU2004242450A1 (en) 2005-01-20
HUS1900056I1 (hu) 2020-02-28
ATE330585T2 (de) 2006-07-15
IL151791A0 (en) 2003-04-10
GB0008660D0 (en) 2000-05-31
EP1449528A1 (en) 2004-08-25
ES2266242T3 (es) 2007-03-01
CN101181263A (zh) 2008-05-21
US20050019271A1 (en) 2005-01-27
NZ535284A (en) 2006-04-28
AU2010200660A1 (en) 2010-03-11
AU776913B2 (en) 2004-09-23
CY1105120T1 (el) 2010-03-03
NO2015024I1 (no) 2015-11-25
ES2266242T5 (es) 2016-10-04
EP2193791A1 (en) 2010-06-09
US7229607B2 (en) 2007-06-12
CN1720995A (zh) 2006-01-18
DK1267866T4 (en) 2016-10-03
JP5042426B2 (ja) 2012-10-03
CA2405705A1 (en) 2001-10-18
HK1050846A1 (en) 2003-07-11
NO2015025I1 (no) 2015-12-07

Similar Documents

Publication Publication Date Title
BR0109875A (pt) Tratamento de doenças respiratórias
BRPI0410721A (pt) composições farmacêuticas espumáveis e métodos para tratamento de um distúrbio
BRPI9908182C1 (pt) composições de proteína de matriz para cura de feridas
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
HRP20020088B1 (hr) Levodopa/karbidopa/entakapon farmaceutski pripravak
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
PT1119543E (pt) N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y
PT1076644E (pt) Aminotetralinas substituidas emn como ligandos para o receptor de neuropeptideoy y5 util no tratamento da obesidade e de outras perturbacoes
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
ATE323473T1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
BR0317134A (pt) Composições e métodos de liberação de agentes farmacológicos
WO2002038171A3 (en) METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
PL373276A1 (en) Trans-epicutaneous administration form for treating restless leg syndrome
ES2125324T3 (es) Film para suministro local de un farmaco para un tratamiento periodontal.
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
WO2001076638A3 (en) Compositions for drug delivery
BR9813319A (pt) Composto, composição farmacêutica para tratamento de infecções bacterianas, e, processos para tratar infecções bacterianas e para preparar um composto
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25I Requirement for requested change of headquarter

Owner name: ARAKIS LTD. (GB)

Free format text: A FIM DE ATENDER AS ALTERACOES DE ENDERECO E NOME REQUERIDAS ATRAVES DA PETICAO NO 20120050097/RJ DE 01/06/2012, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O ENDERECO DO DEPOSITANTE NO ATO DO DEPOSITO E O ENDERECO QUE CONSTA NO DOCUMENTO DE CESSAO COMO TENDO SIDO ALTERADO.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: A PETICAO DE NO 20120050097-RJ, APRESENTADA EM 01/06/2012, EM VIRTUDE DO DISPOSTO NOS ARTS. 218 OU 219 DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA DEVIDO AO INDEFERIMENTO DO PEDIDO DE PATENTE PUBLICADO NA RPI NO 2209, DE 07/05/2013.

B25H Request for change of headquarter rejected

Owner name: ARAKIS LTD. (GB)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]